Genmab A earnings were $1.1B for the trailing 12 months ending Mar 31, 2025, with 46.4% growth year over year. The latest GMAB earnings report on Mar 31, 2025 announced Q1 2025 earnings of $195.0M, down 63.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GMAB reported annual earnings of $1.1B, with 80.2% growth.
GMAB past earnings growth
How has GMAB's earnings growth performed historically?
On GMAB's earnings call on Invalid Date, Genmab A (NASDAQ: GMAB) reported Q1 2025 earnings per share (EPS) of $0.31, up 3.38% year over year. Total GMAB earnings for the quarter were $195.00 million. In the same quarter last year, Genmab A's earnings per share (EPS) was $0.30.
As of the last Genmab A earnings report, Genmab A is currently profitable. Genmab A's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $1.11 billion, a 43.5% increase year over year.
What was GMAB's earnings growth in the past year?
As of Genmab A's earnings date in Invalid Date, Genmab A's earnings has grown 46.37% year over year. This is 34.32 percentage points higher than the US Biotechnology industry earnings growth rate of 12.05%. GMAB earnings in the past year totalled $1.11 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.